Cosmo Pharmaceuticals updates on Uceris®

Dublin - July 6, 2018 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the FDA has approved the Actavis (Teva) generic version of Uceris®. As the patent infringement trial is still ongoing in appeal, if Teva decides to launch at risk, such launch would expose Teva to pay significant damages if the generic is found in infringement by the appeal court.

"We will continue to tenaciously defend and enforce our patent rights on Uceris® in order to profit of exclusivity to its widest extent." said Alessandro Della Chà, Chief Executive Officer of Cosmo Pharmaceuticals.

About Uceris

Uceris® is a locally acting corticosteroid in a novel, patented, oral tablet formulation, which utilizes MMX® multi-matrix technology and is designed to result in the prolonged release and distribution of budesonide throughout the length of the colon. Budesonide has mainly topical anti-inflammatory activity and due to its high first pass metabolism, it has low system bioavailability. Budesonide using MMX® technology may be marketed under another name in some countries.


Media Release (PDF)



Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50